Application progress of hemoglobin-based oxygen carriers (HBOCs) in tumor therapy
10.13303/j.cjbt.issn.1004-549x.2024.04.018
- VernacularTitle:血红蛋白类氧载体在肿瘤治疗领域中的应用进展
- Author:
Shifan ZHENG
1
;
Hong WANG
1
;
Yingcan XU
1
;
Jiakang WU
1
;
Wentao ZHOU
1
;
Shasha HAO
1
Author Information
1. Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu 610051, China
- Publication Type:Journal Article
- Keywords:
hemoglobin-based oxygen carriers(HBOCs);
tumor microenvironment;
tumor hypoxia;
tumor therapy
- From:
Chinese Journal of Blood Transfusion
2024;37(4):477-481
- CountryChina
- Language:Chinese
-
Abstract:
Most solid tumors suffer from inadequate blood perfusion and oxygenation, leading to a hypoxic microenvironment that accelerates tumor progression and adversely impacts prognosis. Thus, improving oxygenation in tumor tissues is crucial for enhancing the sensitivity and efficacy of tumor therapy. Hemoglobin-based oxygen carriers (HBOCs), as a type of oxygen-carrying nanoparticles, can not only carry and release oxygen but also reach the small blood vessels of obstructive microcirculation to deliver oxygen for anoxic tissues and organs, which are difficult for normal red blood cells to pass through. Studies have demonstrated that the application of HBOCs as a potential nanoscale efficient oxygen carrier in tumor therapy can enhance tissue oxygenation and hold great promise for applications in tumor therapy.This review summarizes the impact of hypoxia in tumors and highlights the progress and potential mechanisms of using HBOCs in tumor radiotherapy, chemotherapy, new kinetic therapy and immunotherapy.
